262 related articles for article (PubMed ID: 22963187)
1. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.
Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
Pharmacoeconomics; 2012 Nov; 30(11):1051-65. PubMed ID: 22963187
[TBL] [Abstract][Full Text] [Related]
2. The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand.
Aaltonen K; Ragupathy R; Tordoff J; Reith D; Norris P
Value Health; 2010; 13(1):148-56. PubMed ID: 19744294
[TBL] [Abstract][Full Text] [Related]
3. Access to children's medicines in the United Kingdom, Australia and New Zealand in 1998, 2002 and 2007.
Ragupathy R; Tordoff J; Norris P; Reith D
Pharm World Sci; 2010 Jun; 32(3):386-93. PubMed ID: 20354788
[TBL] [Abstract][Full Text] [Related]
4. Trends in accessibility to medicines for children in New Zealand: 1998-2002.
Chui J; Tordoff J; Kennedy J; Reith D
Br J Clin Pharmacol; 2004 Mar; 57(3):322-7. PubMed ID: 14998428
[TBL] [Abstract][Full Text] [Related]
5. Changes in availability of paediatric medicines in Australia between 1998 and 2002.
Chui J; Tordoff J; Reith D
Br J Clin Pharmacol; 2005 Jun; 59(6):736-42. PubMed ID: 15948941
[TBL] [Abstract][Full Text] [Related]
6. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
7. Access to new medicines in New Zealand compared to Australia.
Wonder M; Milne R
N Z Med J; 2011 Nov; 124(1346):12-28. PubMed ID: 22143849
[TBL] [Abstract][Full Text] [Related]
8. Effect of the pediatric exclusivity provision on children's access to medicines.
Grieve J; Tordoff J; Reith D; Norris P
Br J Clin Pharmacol; 2005 Jun; 59(6):730-5. PubMed ID: 15948940
[TBL] [Abstract][Full Text] [Related]
9. Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.
Taylor C; Wonder M
Aust Health Rev; 2015 Sep; 39(4):455-461. PubMed ID: 25751688
[TBL] [Abstract][Full Text] [Related]
10. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
Gleeson D; Lopert R; Reid P
Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
[TBL] [Abstract][Full Text] [Related]
11. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
[TBL] [Abstract][Full Text] [Related]
12. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand.
Raftery JP
Med J Aust; 2008 Jan; 188(1):26-8. PubMed ID: 18205559
[TBL] [Abstract][Full Text] [Related]
13. Managing pharmaceutical expenditure while increasing access. The pharmaceutical management agency (PHARMAC) experience.
Braae R; McNee W; Moore D
Pharmacoeconomics; 1999 Dec; 16(6):649-60. PubMed ID: 10724792
[TBL] [Abstract][Full Text] [Related]
14. Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002.
Balakrishnan K; Tordoff J; Norris P; Reith D
Br J Clin Pharmacol; 2007 Jan; 63(1):85-91. PubMed ID: 16869822
[TBL] [Abstract][Full Text] [Related]
15. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
16. Government review aims to speed up NHS access to new medicines.
Hawkes N
BMJ; 2014 Nov; 349():g7090. PubMed ID: 25422172
[No Abstract] [Full Text] [Related]
17. Comparing subsidized access to medicines across payer systems.
Wonder M; Milne R
Pharmacoeconomics; 2013 Feb; 31(2):173-4. PubMed ID: 23329425
[No Abstract] [Full Text] [Related]
18. The authors' reply to wonder and milne: "comparing subsidized access to medicines across payer systems".
Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
Pharmacoeconomics; 2013 Feb; 31(2):175-6. PubMed ID: 23329428
[No Abstract] [Full Text] [Related]
19. Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan.
Oye KA; Eichler HG; Hoos A; Mori Y; Mullin TM; Pearson M
Clin Pharmacol Ther; 2016 Dec; 100(6):626-632. PubMed ID: 27618128
[TBL] [Abstract][Full Text] [Related]
20. Response to PHARMAC on Access to new medicines in New Zealand compared to Australia.
Milne R; Wonder M
N Z Med J; 2011 Dec; 124(1347):91-3. PubMed ID: 22237576
[No Abstract] [Full Text] [Related]
[Next] [New Search]
